Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.

Suzuki Y, Fukui N, Tsuneyama N, Watanabe J, Ono S, Sugai T, Saito M, Inoue Y, Someya T.

Hum Psychopharmacol. 2012 Jan;27(1):43-6.

PMID:
22745940
2.

Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.

Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, Ono S, Saito M, Someya T.

J Clin Psychopharmacol. 2013 Jun;33(3):411-4. doi: 10.1097/JCP.0b013e31828ecd52.

PMID:
23609388
3.

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, Kim YK, Kim SH, Han C, Lee MS, Park JY.

J Clin Psychopharmacol. 2009 Jun;29(3):272-7. doi: 10.1097/JCP.0b013e3181a289e0.

PMID:
19440082
4.

Risperidone plasma levels, clinical response and side-effects.

Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. Epub 2004 Nov 29.

PMID:
15565299
5.

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML.

Psychopharmacology (Berl). 1999 Dec;147(3):300-5.

PMID:
10639689
6.

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

Gunes A, Spina E, Dahl ML, Scordo MG.

Ther Drug Monit. 2008 Oct;30(5):628-33. doi: 10.1097/FTD.0b013e3181858ca9.

PMID:
18708991
7.

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T.

J Clin Pharmacol. 2003 Feb;43(2):122-7.

PMID:
12616663
8.

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.

Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY.

Clin Pharmacol Ther. 2005 Nov;78(5):520-8. Epub 2005 Sep 26.

PMID:
16321618
9.

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Bork JA, Rogers T, Wedlund PJ, de Leon J.

J Clin Psychiatry. 1999 Jul;60(7):469-76.

PMID:
10453802
10.

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L.

J Psychopharmacol. 2007 Nov;21(8):837-42. Epub 2007 Aug 22.

PMID:
17715206
11.

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

Yagihashi T, Mizuno M, Chino B, Sato Y, Sakuma K, Takebayashi T, Takao T, Kosaki K.

Hum Psychopharmacol. 2009 Jun;24(4):301-8. doi: 10.1002/hup.1025.

PMID:
19387994
12.

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.

Int Clin Psychopharmacol. 2005 Mar;20(2):71-8.

PMID:
15729081
13.

Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.

Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, de Vries R, Kaneko S.

Ther Drug Monit. 2003 Jun;25(3):287-93.

PMID:
12766554
14.

Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.

Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR.

Ther Drug Monit. 2012 Apr;34(2):182-7. doi: 10.1097/FTD.0b013e3182489a6f.

PMID:
22377743
15.

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.

Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L.

Eur J Clin Pharmacol. 2001 Nov;57(9):671-5.

PMID:
11791898
16.

A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.

Locatelli I, Kastelic M, Koprivsek J, Kores-Plesnicar B, Mrhar A, Dolzan V, Grabnar I.

Eur J Pharm Sci. 2010 Oct 9;41(2):289-98. doi: 10.1016/j.ejps.2010.06.016. Epub 2010 Jul 3.

PMID:
20599499
17.

Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.

Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM.

J Clin Pharmacol. 2010 Jun;50(6):659-66. doi: 10.1177/0091270009347867. Epub 2010 Mar 23.

PMID:
20332423
18.

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

Mannheimer B, von Bahr C, Pettersson H, Eliasson E.

Ther Drug Monit. 2008 Oct;30(5):565-9. doi: 10.1097/FTD.0b013e31818679c9.

PMID:
18728628
19.

Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.

Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, Bickel GG, Bondolfi G, Conus P, Eap CB.

J Clin Psychopharmacol. 2013 Jun;33(3):289-98. doi: 10.1097/JCP.0b013e31828f62cd.

PMID:
23609392
20.

Plasma risperidone concentrations during combined treatment with sertraline.

Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A.

Ther Drug Monit. 2004 Aug;26(4):386-90.

PMID:
15257068
Items per page

Supplemental Content

Write to the Help Desk